Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | IDH1 | O75874 | 16/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19104435 | 0.82 | IDH1 (0.69) | IDH1 | |
| SCHEMBL17009727 | 0.82 | IDH1 (0.69) | IDH1 | |
| SCHEMBL20685199 | 0.82 | IDH1 (0.69) | IDH1 | |
| SCHEMBL20685200 | 0.82 | IDH1 (0.69) | IDH1 | |
| SCHEMBL17009724 | 0.82 | IDH1 (0.69) | IDH1 | |
| SCHEMBL17009721 | 0.82 | IDH1 (0.69) | IDH1 | |
| SCHEMBL21311021 | 0.81 | RPS6KB1 (0.57) | RPS6KB1KDM4EIDH1L3MBTL1 | |
| SCHEMBL19029395 | 0.80 | KDM4E (0.56) | KDM4EFGFR1 | |
| SCHEMBL20465152 | 0.79 | RPS6KB1 (0.55) | RPS6KB1KDM4EIDH1 | |
| SCHEMBL30158822 | 0.77 | MEN1 (0.56) | RPS6KB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829448-B2 | Substituted benzoimidazoles as modulators of ROR-γ | VITAE PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3331876-B1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200062707-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. | 2020-02-27 | — | — | US | disclosed |
| WO-2017024018-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062707-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | RPS6KB1 191/4885KDM4E 3259/4885IDH1 3584/4885 |
| US-10829448-B2 | Substituted benzoimidazoles as modulators of ROR-γ | RORC, RORB, RORA | RPS6KB1 401/4885KDM4E 1874/4885IDH1 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.